Primecap Management Co. CA Sells 215,400 Shares of Cerus Corporation $CERS

Primecap Management Co. CA trimmed its holdings in shares of Cerus Corporation (NASDAQ:CERS) by 16.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,100,000 shares of the biotechnology company’s stock after selling 215,400 shares during the period. Primecap Management Co. CA’s holdings in Cerus were worth $1,749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Cerus by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after purchasing an additional 62,663 shares in the last quarter. Wasatch Advisors LP boosted its stake in shares of Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock valued at $12,033,000 after purchasing an additional 213,917 shares in the last quarter. Millennium Management LLC increased its holdings in Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock valued at $4,479,000 after buying an additional 344,395 shares during the period. Acadian Asset Management LLC increased its holdings in Cerus by 38.6% during the second quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock valued at $3,710,000 after buying an additional 733,683 shares during the period. Finally, Ieq Capital LLC raised its stake in Cerus by 4.2% in the second quarter. Ieq Capital LLC now owns 2,418,263 shares of the biotechnology company’s stock worth $3,410,000 after buying an additional 97,467 shares in the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Trading Down 1.5%

Cerus stock opened at $2.56 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.89. The stock has a market cap of $491.75 million, a PE ratio of -32.00 and a beta of 1.52. The stock has a 50-day moving average of $2.30 and a two-hundred day moving average of $1.81. Cerus Corporation has a one year low of $1.12 and a one year high of $2.95.

Wall Street Analysts Forecast Growth

CERS has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Wall Street Zen raised shares of Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.